All In Biotech

Drug Trial Radar · NCT00909857

Effect on Primary Dysmenorrhea

A Multi-center, Double-blind, Double-dummy, Randomized, Controlled, Parallel-group Study to Assess Efficacy and Safety of SH T00658ID Compared to SH D593B in the Treatment of Primary Dysmenorrhea

Last checked: Nov 20, 2026Latest source record: Aug 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 507 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

507

Actual

Start

Apr 2009

Primary completion

Nov 2010

Study completion Nov 2010

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
May 29, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
Female only, from 14 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To investigate the potential benefits of a new oral contraceptive (SH T00658ID) on alleviating complaints of dysmenorrhea associated with oral contraceptive use.

Conditions

  • Primary Dysmenorrhea

Interventions

  • Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Drug

    Daily oral administration of one tablet SH T00658ID for 28 days per cycle in the respective treatment period; no tablet-free interval

  • Ethinyl estradiol, Levonorgestrel (Miranova)Drug

    Daily oral administration of one tablet for 28 days per cycle in the respective treatment period; no tablet-free interval

  • Placebo Match to SH T00658IDDrug

    Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.

  • Placebo Match to SH D593BDrug

    Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Number of Days With Dysmenorrheic PainTime frame: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

Locations

41 sites in 6 countries. Site status is shown where the registry gives one.

  • Site not named

    Tucson, Arizona

  • Site not named

    San Diego, California

  • Site not named

    Hialeah, Florida

  • Site not named

    Leesburg, Florida

  • Site not named

    Sandy Springs, Georgia

  • Site not named

    Idaho Falls, Idaho

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    La Crosse, Wisconsin

  • Site not named

    Langley, British Columbia, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Pointe-Claire, Quebec, Canada

  • Site not named

    Ste-Foy, Quebec, Canada

  • Site not named

    Regina, Saskatchewan, Canada

  • Site not named

    Santiago, Chile

  • Site not named

    Talcahuano, Chile

  • Site not named

    Temuco, Chile

  • Site not named

    Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • Site not named

    Hamburg, Free and Hanseatic City of Hamburg, Germany

  • Site not named

    Cologne, North Rhine-Westphalia, Germany

  • Site not named

    Essen, North Rhine-Westphalia, Germany

  • Site not named

    Leipzig, Saxony, Germany

  • Site not named

    Bernburg, Saxony-Anhalt, Germany

  • Site not named

    Magdeburg, Saxony-Anhalt, Germany

  • Site not named

    Bologna, Italy

  • Site not named

    Brescia, Italy

  • Site not named

    Milan, Italy

  • Site not named

    Modena, Italy

  • Site not named

    Perugia, Italy

  • Site not named

    Roma, Italy

  • Site not named

    Siena, Italy

  • Site not named

    Torino, Italy

  • Site not named

    Udine, Italy

  • Site not named

    Francavilla Fontana, Brindisi, Italy

  • Site not named

    Cebu, Philippines

  • Site not named

    Cebu City, Philippines

  • Site not named

    Davao City, Philippines

  • Site not named

    Metro Manila, Philippines

  • Site not named

    Metro Manila, Philippines

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.